The authors wish to make the following corrections to our previously published paper [1]. The correct reference order in Figure 1 should be:
Due to the partially incorrect references shown in the figure and tables, the correct reference order in Table 1 should be:
In Section 2.2, since the reference order has been updated, the correct reference order in this section should be:
When TET1 is used as an effector protein for DNA demethylation, as in DNMT, its catalytic domain is frequently used in epigenome editing [9,26,28,32,41,44,45] (Figure 1 and Table 2). It has also been reported that the catalytic domain of TET2 is fused with zinc finger [46];
The application of the SunTag system to tether multiple TET1 proteins to increase the efficiency of DNA demethylation in the target sequence has also been reported [41] (Figure 1 and Table 2);
Morita et al. reported no significant difference in DNA demethylation activity between dCas9–TET1 and dCas9–catalytically dead Tet1 (dTet1) on the Gfap and H19 loci, whereas the dCas9–SunTag system, which enables the tethering of multiple copies of TET1, has strong DNA demethylation activity [41];
On the other hand, other groups have reported that the dCas9–TET1 system is sufficient to decrease DNA methylation in target loci [9,28,32,45,47];
In this system, the effector protein is fused with the Pumilio/FBF RNA-binding domain (PUF domain) and a DNA-binding module comprising a dCas9 and gRNA complex in which multiple PUF binding sites are expressed together with single guide (sg) RNA [48];
Taghbalout et al. reported increased efficiency of DNA demethylation and derepression of genes by multiple tethering of TET1 by a Casilio complex named “Casilio–ME1” compared with the efficiency of DNA demethylation by the dCas9–SunTag system [42].
Due to the partially incorrect references shown in the figure and tables, the correct reference order in Table 2 should be:
Editing DNA methylation with ten-eleven translocation (TET) proteins.
Target | DNA-Binding Module | Effector | References |
---|---|---|---|
KLF4, RHOX, HBB | TALE | TET1 CD | [44] |
ICAM1 | Zinc Finger | TET2 CD | [46] |
AscI | TALE-CIB1 | TET1 CD-CRY2 | [26] |
Snrpn, BDNF, MyoD | dCas9 | TET1 CD | [28] |
Gfap, H19 DMR | dCas9-SunTag | scFv-TET1 CD | [41] |
BRCA1 | dCas9 | TET1 CD | [45] |
FMR1 | dCas9 | TET1 CD | [9] |
Sox1 | dCas9 | TET1 CD | [47] |
IAP (Agouti) | dCas9 | TET1 CD | [32] |
hMLH1 | dCas9 + gRNA withPUFa-binding site | PUFa-TET1 CD with GADD45A or NEIL2 | [42] |
In Section 4, since the reference order has been updated, the correct reference order in this section should be:
The application of DNA methylation editing in vivo has also been reported for human clinical therapy in fetal and adult brains [9,41].
In the reference section, the correct reference should be:
41. Morita, S.; Noguchi, H.; Horii, T.; Nakabayashi, K.; Kimura, M.; Okamura, K.; Sakai, A.; Nakashima, H.; Hata, K.; Nakashima, K.; et al. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. Nat. Biotechnol. 2016, 34, 1060–1065.
42. Taghbalout, A.; Du, M.; Jillette, N.; Rosikiewicz, W.; Rath, A.; Heinen, C.D.; Li, S.; Cheng, A.W. Enhanced CRISPR-based DNA demethylation by Casilio-ME-mediated RNA-guided coupling of methylcytosine oxidation and DNA repair pathways. Nat. Commun. 2019, 10, 4296.
46. Chen, H.; Kazemier, H.G.; de Groote, M.L.; Ruiters, M.H.; Xu, G.L.; Rots, M.G. Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter. Nucleic Acids Res. 2014, 42, 1563–1574.
47. Baumann, V.; Wiesbeck, M.; Breunig, C.T.; Braun, J.M.; Koferle, A.; Ninkovic, J.; Gotz, M.; Stricker, S.H. Targeted removal of epigenetic barriers during transcriptional reprogramming. Nat. Commun. 2019, 10, 2119.
48. Cheng, A.W.; Jillette, N.; Lee, P.; Plaskon, D.; Fujiwara, Y.; Wang, W.; Taghbalout, A.; Wang, H. Casilio: A versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling. Cell Res. 2016, 26, 254–257.
The authors would like to apologize for any convenience caused to the readers by these changes.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure and Tables
Figure 1. Schematic diagrams of artificial enzymes for editing DNA methylation. Representative combinations of DNA-binding modules and effectors are shown. Zinc finger, transcription activator-like effector (TALE), and dCas9 with guide RNA (gRNA) complex are used for DNA-binding modules. DNMT3A or M.SssI are effectors of inducing DNA methylation. To remove DNA methylation, the catalytic domain (CD) of TET1 is fused with DNA binding module. SunTag technology enables multiple copies of TET1 CD to be introduced to the target region [41]. There has been a report describing the tethering of both TET1 CD and base excision repair (BER)-related proteins such as GADD45A to improve the efficiency of DNA demethylation [42].
Editing DNA methylation with methyltransferases.
Target | DNA-Binding Module | Effector | References |
---|---|---|---|
Maspin | Zinc Finger | DNMT3A CD | [18] |
VEGF-A | Zinc Finger | DNMT3A CD-DNMT3L | [19] |
HBV x promoter | Zinc Finger | DNMT3A C-term | [20] |
Line1 | Zinc Finger | MIWI2 | [23] |
P16 (CDKN2A) | TALE | DNMT3A-DNMT3L | [24] |
Major satellite | TALE, dCas9 | SssI | [25] |
AsclI | TALE-CIB1 | DNMT3A CD-CRY2 | [26] |
BACH-2, IL6ST | dCas9 | DNMT3A CD | [27] |
Snrpn, CTCF | dCas9 | DNMT3A | [28] |
Hox genes, Runx1, H19 | dCas9 | SssI (Q147L) | [29] |
SALL2, HBG | dCas9 | Split SssI | [30] |
HoxA5, KLF4 | dCas9-SunTag | scFv-DNMT3A | [31] |
IAP (Agouti), H19,IG-DMR, Snrpn DMR | dCas9 | DNMT3A | [32] |
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021 by the authors.
Abstract
Target DNA-Binding Module Effector References KLF4, RHOX, HBB TALE TET1 CD [44] ICAM1 Zinc Finger TET2 CD [46] AscI TALE-CIB1 TET1 CD-CRY2 [26] Snrpn, BDNF, MyoD dCas9 TET1 CD [28] Gfap, H19 DMR dCas9-SunTag scFv-TET1 CD [41] BRCA1 dCas9 TET1 CD [45] FMR1 dCas9 TET1 CD [9] Sox1 dCas9 TET1 CD [47] IAP (Agouti) dCas9 TET1 CD [32] hMLH1 dCas9 + gRNA withPUFa-binding site PUFa-TET1 CD with GADD45A or NEIL2 [42] In Section 4, since the reference order has been updated, the correct reference order in this section should be: Zinc finger, transcription activator-like effector (TALE), and dCas9 with guide RNA (gRNA) complex are used for DNA-binding modules. Target DNA-Binding Module Effector References Maspin Zinc Finger DNMT3A CD [18] VEGF-A Zinc Finger DNMT3A CD-DNMT3L [19] HBV x promoter Zinc Finger DNMT3A C-term [20] Line1 Zinc Finger MIWI2 [23] P16 (CDKN2A) TALE DNMT3A-DNMT3L [24] Major satellite TALE, dCas9 SssI [25] AsclI TALE-CIB1 DNMT3A CD-CRY2 [26] BACH-2, IL6ST dCas9 DNMT3A CD [27] Snrpn, CTCF dCas9 DNMT3A [28] Hox genes, Runx1, H19 dCas9 SssI (Q147L) [29] SALL2, HBG dCas9 Split SssI [30] HoxA5, KLF4 dCas9-SunTag scFv-DNMT3A [31] IAP (Agouti), H19,IG-DMR, Snrpn DMR dCas9 DNMT3A [32]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Division of Biomedical Research, Kitasato University Medical Center, Kitasato University, 6-100 Arai, Kitamoto, Saitama 364-8501, Japan;
2 Faculty of Biology-Oriented Science and Technology, KINDAI University, 930 Nishimitani, Kinokawa, Wakayama 649-6493, Japan;